Healthcare

Inhalation Anesthesia Global Market 2024 – By Trends, Key Drivers, Top Manufacturers, Opportunities Forecast To 2033 | Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA

The Inhalation Anesthesia by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Inhalation Anesthesia Market:
https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

According to The Business Research Company’s Inhalation Anesthesia , The inhalation anesthesia market size has grown strongly in recent years. It will grow from $1.46 billion in 2023 to $1.56 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to growing surgical procedures requiring anesthesia, increased geriatric population, development of inhalation anesthetics, expansion of ambulatory surgical centers, increasing prevalence of chronic diseases such as heart disease and cancer.

The inhalation anesthesia market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising demand for minimally invasive surgeries, growing global healthcare expenditure, increasing number of surgical procedures in emerging markets, adoption of inhalation anesthesia in veterinary medicine, increased government funds for r&d of innovative inhalation anesthetics. Major trends in the forecast period include technological innovations in anesthesia delivery systems, development of inhalation anesthesia devices for pediatric use, shift towards sevoflurane and desflurane, focus on eco-friendly anesthetic agents, integration of monitoring technologies in anesthesia delivery.

The increasing geriatric population is anticipated to propel the growth of inhalation anesthesia during the forecast period. The increasing geriatric population is boosting the inhalation anesthesia market as they are highly prone to degenerative diseases and chronic illnesses, which eventually leads to a rise in surgeries and therapeutics. Moreover, the increasing geriatric population, which is more susceptible to ailments, such as cardiovascular, neurological, respiratory, and degenerative disorders, is boosting the market growth. It is usually inconvenient to administer anesthesia through an intravenous route to geriatric patients due to punctured blood vessels and issues with patient compliance. For instance, in October 2022, according to the World Health Organization, a Switzerland-based international public health organization, the global population of individuals aged 60 years is projected to increase to 1.4 billion by 2022 compared to 1 billion in 2020. Moreover, 1 out of 6 people in the world will be aged more than 60 years or older by 2030. Therefore, the increasing geriatric population is expected to boost demand for inhalation anesthesia during the forecast period.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=7198&type=smp

The inhalation anesthesia market covered in this report is segmented –
1) By Product: Sevoflurane, Desflurane, Isoflurane, Nitrous Oxide
2) By Application: Induction, Maintenance
3) By End User: Hospitals, Ambulatory Surgical Centers

Many companies operating in inhalation anesthesia are developing innovative products such as Sedaconda to meet industry demands and strengthen the market position across the globe. Sedaconda is an inhaled sedation therapy delivered using the Anaesthetic Conserving Device (ACD) and approved for use in intensive care. For instance, in February 2022, Sedana Medical AB, a Sweden based med tech and pharmaceutical company introduced Sedaconda (isoflurane) to the German market. Sedaconda (isoflurane) is delivered using the medical device known as Sedaconda ACD (Anaesthetic Conserving Device) and is the sole approved inhaled sedation therapy authorized for use in intensive care settings. Following the European DCP approval in July 2021, Sedaconda (isoflurane) has received national approvals in 14 countries.

The inhalation anesthesia market report table of contents includes:
1. Executive Summary
2. Inhalation Anesthesia Market Characteristics
3. Inhalation Anesthesia Market Trends And Strategies
4. Inhalation Anesthesia Market – Macro Economic Scenario
5. Global Inhalation Anesthesia Market Size and Growth
……………..
31. Global Inhalation Anesthesia Market Competitive Benchmarking
32. Global Inhalation Anesthesia Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Inhalation Anesthesia Market
34. Inhalation Anesthesia Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Good PR News